Vaccinex’s mission is to deliver innovative therapies that improve the lives of patients and provide treatment solutions for critical unmet needs. Through deep understanding of science and pathology of disease, we are pioneering a differentiated approach to treating neurologic diseases and cancer with novel antibody therapeutics. We are grateful to the patients, families, and the clinical staff that participate in our clinical trials. Each individual’s participation contributes to the potential to realize benefits for patients today and to advance our understanding of disease for the next generation.
Click to download
Clinical trials evaluating pepinemab for the treatment of cancer including Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Recruiting
NCT04815720
Keynote B84 Head and Neck Cancer
Evaluating the Safety and Efficacy of our Drug Pepinemab in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Phase 1b/2
Condition(s) Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
SPONSOR
COLLABORATOR
Merck Sharp & Dohme Corp.
To learn more about the details of this trial, select your role:
Recruiting
NCT03690986
Integrated Biomarker Trial – Head and Neck Cancer
Integrated Biomarker Trial of Pepinemab in Combination with Ipilimumab or Nivolumab in Patients with Head and Neck Cancer.
Phase 1
Condition(s) Squamous Cell Carcinoma of the Head and Neck
SPONSOR
Emory University
COLLABORATOR
Vaccinex
Recruiting
NCT03769155
Integrated Biomarker Trial – Melanoma
Integrated Biomarker Trial of Pepinemab with or without Ipilimumab and/or Nivolumab in Patients with Resectable Stage IIIB-D Melanoma.
Phase 1
Condition(s) Cutaneous Melanoma
SPONSOR
Emory University
COLLABORATOR
Bristol Myers Squibb
Vaccinex
Recruiting
NCT05102721
Pancreatic Adenocarcinoma
Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
Phase 1b/2
Condition(s) Metastatic pancreatic adenocarcinoma refractory to first line chemotherapy
SPONSOR
COLLABORATOR
University of Rochester & Merck KGaA
To learn more about the details of this trial, select your role:
Recruiting
NCT05378464
Adoptive Cell Therapy trial – Breast Cancer
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Phase 1
Condition(s) Metastatic Breast Cancer
SPONSOR
H. Lee Moffitt Cancer Center and Research Institute
COLLABORATOR
Vaccinex
Completed
NCT03268057
CLASSICAL – Lung Cancer
Evaluating the Safety and Efficacy of our Drug Pepinemab in Combination with Avelumab in Patients with Advanced Non-Small Cell Lung Cancer.
Phase 1b/2
Condition(s) Carcinoma, Non-Small-Cell Lung
SPONSOR
COLLABORATOR
Merck KGaA, Darmstadt, Germany
Active, not recruiting
NCT03320330
Treating Younger Patients with Recurrent, Relapsed or Refractory Solid Tumors
Pepinemab, a Humanized Monoclonal Antibody to Semaphorin 4D, in Pediatric Patients with Relapsed or Refractory Solid Tumors.
Phase 1/2
Condition(s) Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma
SPONSOR
Children's Oncology Group
COLLABORATOR
National Cancer Institute (NCI)
Vaccinex